|
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITINGPhase 1Sponsored by TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Actively Recruiting
PhasePhase 1
SponsorTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Started2025-03-31
Est. completion2027-08
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations16 sites
View on ClinicalTrials.gov →
NCT06917079
Summary
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation * Measurable disease by RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1 * Life expectancy \>24 weeks * Adequate organ function Exclusion Criteria: * Malignancy within the last 2 years as specified in the protocol * Untreated brain metastases Other inclusion/exclusion criteria are specified in the protocol.
Conditions16
Advanced Lung CarcinomaCRC (Colorectal Cancer)CancerKRAS G12AKRAS G12CKRAS G12DKRAS G12SKRAS G12VLung CancerMetastatic Colorectal Cancer (CRC)
Interventions12
Locations16 sites
The Angeles Clinic and Research Institute - West Los Angeles Office
310-582-7900
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
415-885-7796
Yale University
New Haven, Connecticut, 06510
203-200-2486
Find trials near these locations
Cancer trials in Los AngelesCancer trials in SacramentoCancer trials in San DiegoCancer trials in San FranciscoCancer trials in TampaCancer trials in BostonCancer trials in New YorkCancer trials in NashvilleCancer trials in DallasCancer trials in HoustonCancer trials in San AntonioCancer trials in SeattleAll trials in CaliforniaAll trials in FloridaAll trials in IllinoisAll trials in MassachusettsAll trials in New YorkAll trials in TennesseeAll trials in TexasAll trials in Washington
Related trials
- Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer — TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors — TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer — Tianjin Medical University Cancer Institute and Hospital
- A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers — Hummingbird Bioscience
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer — Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- AK129 Combination Therapy for Advanced Solid Tumors — Akeso
- ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors — Hansoh BioMedical R&D Company
- BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation of Next Generation CRC Treatment — Pierre Fabre Pharma GmbH
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 1
SponsorTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Started2025-03-31
Est. completion2027-08
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations16 sites
View on ClinicalTrials.gov →
NCT06917079